Learn Data Labs About Find trials matched to me

About Learn Data Labs Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Take an antibiotic alongside standard tuberculosis treatment | stella

Back to Tuberculosis trials

Recruiting

Testing an antibiotic to protect lungs in tuberculosis patients

Plain-English translation of NCT05473520 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether , a common antibiotic, can help protect your lungs when added to your standard tuberculosis medications. Researchers believe this medication might reduce lung damage and help you recover lung function better. You would take it for 8 weeks while also taking your regular TB medications, then continue with your TB treatment alone.

Tuberculosis can permanently damage the lungs even after the infection is cured, sometimes leading to breathing problems and serious heart complications. This trial is testing whether this medication might prevent or reduce that damage, which could help you stay healthier long-term.

Do you qualify?

You likely qualify if…

you are 21 years old or older
you have been recently diagnosed with pulmonary tuberculosis confirmed by lab tests
you have lung cavities visible on your chest X-ray
you have had 7 or fewer days of TB treatment, or are about to start treatment
you are able and willing to provide informed consent and complete all follow-up visits

You likely don't qualify if…

you have HIV co-infection
you have had tuberculosis before
you have severe lung disease such as pulmonary fibrosis, bronchiectasis, COPD, or lung cancer
you are pregnant, breastfeeding, or allergic to tetracycline antibiotics
you have an autoimmune disease or are taking medications that suppress your immune system

What participation looks like

You will be randomly assigned to either receive or a placebo (dummy pill), both taken twice daily for 8 weeks alongside your regular TB medications. Over 24 months of follow-up, you'll have lung function tests, chest imaging, heart tests, and blood samples taken at different time points to track how well your lungs are healing. All participants continue their standard TB treatment for the full course as prescribed by their doctor.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(6 sites)

Malaysia

Hospital Queen Elizabeth I, Kota Kinabalu, Sabah

Klinik Kesihatan Luyang, Kota Kinabalu, Sabah

Klinik Kesihatan Menggatal, Kota Kinabalu, Sabah

Universiti Malaysia Sabah (UMS), Borneo Medical and Health Research Centre, Kota Kinabalu, Sabah

Singapore

National University Hospital, Singapore

Key details

Phase

Large-scale testing

Sponsor

National University Hospital, Singapore

Collaborators

Tan Tock Seng Hospital, Hospital Queen Elizabeth, Malaysia

Enrollment target

~150 participants

Started

May 2023

Primary completion

January 2030

Age range

21 Years and older

Last updated on clinicaltrials.gov in September 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Srishti CHHABRA, MBBS BSc MRCP

National University Hospital, Singapore

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov